Biotechnology Company Announces Preclinical Data: Type 2 NKT Activating Molecules

GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio,” “we,” “our,” or the “Company”), a biotechnology company advancing an innovative pipeline of Natural Killer T (NKT) cell modulators for the treatment of inflammatory, fibrotic, and autoimmune diseases, today announced the presentation of encouraging preclinical data at the 14th International Congress on Autoimmunity held May 17-20, 2024, in Ljubljana, Slovenia (the Congress). Dr. Vipin Kumar Chaturvedi, Chief Scientific Officer of GRI Bio, unveiled the promising results from the Company’s preclinical studies on type 2 NKT activating molecules, GRI-0803 and GRI-0124. $GRI Bio(GRI.US)$